LEP and metabolic dysfunction-associated steatotic liver disease: A 2015 meta-analysis [47] reported higher circulating leptin levels in MASLD patients compared to controls, while a 2024 meta-analysis by Makri and colleagues [48] found no difference in circulating leptin levels between MASLD patients without fibrosis and controls, but significantly higher levels in those with fibrosis.